Tidbits from today's presentation3Q2021 - Commence Phase 1b clinical studies for GBM and NSCLC
4Q2021 - Enrol and treat 10 GBM and 10 NSCLC patients Canada
2021 - Breakthrough Designation from FDA for results of first 20 - 25 patients
Theralase has no affiliation with the study being conducted by Roswell Park and Dr. McFarland
FDA requirement for CR at 360 days is 360 days post the initial CR, not 360 days post the initial treatment. This has been done at the FDA's request and has lengthened the duration of the phase 2 study. Competing treatments such as Merck's Keytruda measured 360 day CR from the initial treatment which gives their results an advantage over Theralase as it represents a shorter duration.